EWM
BMRN icon

Endurance Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Endurance Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,000
Closed -$82 – 491
2016
Q1 		$82 Buy
+1,000
New +$81.4K 0.01% 229

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Endurance Wealth Management's BMRN Position: Q2 2016 in Review

Endurance Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 1,000 shares — an estimated $82 sold.

Endurance Wealth Management first reported a position in BMRN in Q1 2016 and held it in 1 quarter. The position peaked at $82 in Q1 2016. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

  • Endurance Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Endurance Wealth Management sold 1,000 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $82.
  • Endurance Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Endurance Wealth Management's BioMarin Pharmaceuticals position peaked at $82 in Q1 2016.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Endurance Wealth Management's 13F filing for Q2 2016, filed 4 Aug 2016.